Gadolinium retention concerns have pushed MRI contrast toward using as little gadolinium as diagnostically possible. Elucirem (gadopiclenol) was designed for exactly that.
Its relaxivity is roughly double that of conventional agents, allowing comparable image quality at half the standard gadolinium dose. The macrocyclic contrast agent is used with MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and the body.
Halving gadolinium exposure is Elucirem’s core clinical and commercial argument in a category otherwise competing largely on price. Its macrocyclic structure also confers the greater stability associated with lower retention risk, making dose-reduction policy the main driver of adoption.
